Cover Image
市場調查報告書

前列腺癌治療藥的全球市場:∼2020年

Global Prostate Cancer Therapeutics Market to 2020

出版商 Renub Research 商品編碼 344767
出版日期 內容資訊 英文 80 Pages; 35 Figures; 2 Tables
商品交期: 最快1-2個工作天內
價格
Back to Top
前列腺癌治療藥的全球市場:∼2020年 Global Prostate Cancer Therapeutics Market to 2020
出版日期: 2015年11月06日 內容資訊: 英文 80 Pages; 35 Figures; 2 Tables
簡介

前列腺癌的市場上,對於可滿足延長存活期和減輕毒性、改善無惡化存活期、有效性的改善、低成本化等未滿足需求的新藥物,存在著龐大需求。主要由於荷爾蒙抗性前列腺癌的治療藥的成長等要素使該市場成長,由於新藥物的引進等,該市場規模預計2020年成長到近2倍。

本報告提供全球前列腺癌治療藥的市場相關調查、前列腺癌的風險因素/症狀/診斷/階段等概要、前列腺癌治療藥概要、荷爾蒙治療、化療、免疫療法等主要的治療方法的主要藥物的銷售額規模的變化與預測、市場成長的推進因素及課題分析等彙整資料。

第1章 摘要整理

第2章 前列腺癌:概要

  • 前列腺癌:簡介
  • 風險因素
    • 年齡
    • 人種
    • 家族病史/遺傳
    • 飲食習慣/生活習慣
    • 肥胖
    • 前列腺的感染疾病/發炎
  • 症狀
  • 診斷
    • 直腸手指診斷 (DRE)
    • 攝護腺特異性抗原(PSA)價值檢測血液檢驗
    • 超音波、切片檢查
    • 骨掃描
    • 電腦斷層掃描&MRI
    • PET&SPECT掃描
    • 淋巴節切片檢查
    • ProstaScint掃描
  • 前列腺癌的階段
    • 階段I
    • 階段II
    • 階段III
    • 階段IV

第3章 全球前列腺癌治療藥市場

第4章 全球前列腺癌的發病率

第5章 全球前列腺癌治療藥市場佔有率

第6章 全球前列腺癌荷爾蒙治療藥的銷售額預測

  • 黃體激素:放出荷爾蒙 (LHRH) 拮抗劑
    • Zytiga
    • Gonax / Firmagon
  • 黃體激素:放出荷爾蒙 (LHRH) 類似體
    • Lupron
    • Zoladex
    • Decapeptyl
    • Eligard
    • Vantas
    • Leuplin
  • 抗雄性素
    • Casodex
    • Xtandi、MDV3100
    • Xtandi US、MDV3100

第7章 全球前列腺癌的化療治療藥的市場

  • Taxotere
  • Jevtana

第8章 全球前列腺癌的免疫療法治療藥的市場

  • Provenge

第9章 全球前列腺癌的標靶治療治療藥的市場

  • Xofigo、Alpharadin

第10章 全球前列腺癌市場成長推進因素

  • 關於創新的藥物
  • 癌症治療領域的發展
  • 基因學&蛋白質體學的發展

第11章 全球前列腺癌市場上課題

  • 前列腺癌治療藥的成本
  • 副作用
  • 成功率低

圖表

目錄

The prostate cancer drugs market is expected to nearly double by 2020, due to the introduction of new, more expensive drugs. Prostate Cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost. The global market for the prostate cancer therapeutics market is increasing, driven primarily by the growth in the hormone-refractory prostate cancer therapeutics market. Although, the prostate cancer market faces some hindrances such as the high cost of prostate cancer drugs, the market for prostate cancer drugs is likely to rise in the future.

Global Prostate Cancer Drugs Analysis: Zytiga was the leading prostate cancer drugs in 2014 being followed by Xtandi drugs. In prostate cancer drugs market, Leuplin and Zoladex stand at the third and fourth position respectively in 2014, while Lupron stands at the fifth position in the same year. Bayer's cancer drug Xofigo is also increasing its market share. Decapeptyl, Taxotere, Jevtana and Provenge are the other popular prostate cancer drugs in the global market.

Renub Research report titled “Global Prostate Cancer Therapeutics Market to 2020” provides a comprehensive assessment of the fast-evolving, high-growth of Prostate Cancer Therapeutics Market. This 80 page report with 35 Figures and 2 Tables analyses the Prostate Cancer Therapy Drugs Market, driving factors and challenges for prostate cancer market landscape.

The report covers the following:

1. Global Prostate Cancer - Hormonal Therapy Drugs Market

  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
    • 1. Zytiga
    • 2. Gonax
  • Luteinizing Hormone-Releasing Hormone (LHRH) Analogs
    • 1. Lupron
    • 2. Zoladex
    • 3. Decapeptyl
    • 4. Eligard
    • 5. Vantas
    • 6. Leuplin
  • Anti-Androgens
    • 1. Casodex
    • 2. Xtandi or MDV3100
    • 3. Xtandi US or MDV3100

2. Global Prostate Cancer Chemotherapy Drugs Market

  • 1. Taxotere
  • 2. Jevtana

3. Global Prostate Cancer Immunotherapy Drugs Market-

  • 1. Provenge

4. Global Prostate Cancer Targeted Therapy Drugs Market-

  • 1. Xofigo or Alpharadin

DATA SOURCES

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Table of Contents

1. Executive Summary

2. Prostate Cancer - Overview

  • 2.1. Prostate Cancer Introduction
  • 2.2. Risk Factors
    • 2.2.1. Age
    • 2.2.2. Race
    • 2.2.3. Family History/Genetics
    • 2.2.4. Diet/Lifestyle Factors
    • 2.2.5. Obesity
    • 2.2.6. Infection/Inflammation of the Prostate Gland
  • 2.3. Disease Symptoms
  • 2.4. Diagnosis
    • 2.4.1. Digital Rectal Exam (DRE)
    • 2.4.2. Prostate Specific Antigen (PSA) Blood Test
    • 2.4.3. Prostate Ultrasound and Biopsy
    • 2.4.4. Bone Scan
    • 2.4.5. CT Scan & MRI
    • 2.4.6. PET & SPECT Scan
    • 2.4.7. Lymph Node Biopsy
    • 2.4.8. ProstaScint Scan
  • 2.5. Stages of Prostate Cancer
    • 2.5.1. Stage I
    • 2.5.2. Stage II
    • 2.5.3. Stage III
    • 2.5.4. Stage IV

3. Global Prostate Cancer Drugs Market

4. Global Prostate Cancer Incidence

5. Global Prostate Cancer Drugs Market Share

6. Global Prostate Cancer - Hormonal Therapy Drugs Sales & Forecast to 2020

  • 6.1. Luteinizing Hormone - Releasing Hormone (LHRH) Antagonists
    • 6.1.1. Zytiga
    • 6.1.2. Gonax / Firmagon
  • 6.2. Luteinizing Hormone - Releasing Hormone (LHRH) Analogs
    • 6.2.1. Lupron
    • 6.2.2. Zoladex
    • 6.2.3. Decapeptyl
    • 6.2.4. Eligard
    • 6.2.5. Vantas
    • 6.2.6. Leuplin
  • 6.3. Anti - Androgens
    • 6.3.1. Casodex
    • 6.3.2. Xtandi or MDV3100
    • 6.3.3. Xtandi US or MDV3100

7. Global Prostate Cancer - Chemotherapy Drugs Market

  • 7.1. Taxotere
  • 7.2. Jevtana

8. Global Prostate Cancer - Immunotherapy Drugs Market

  • 8.1. Provenge

9. Global Prostate Cancer - Targeted Therapy Drugs Market

  • 9.1. Xofigo or Alpharadin

10. Global Prostate Cancer Market - Driving Factors

  • 10.1. Introduction of Innovative Drugs
  • 10.2. Advancement in Oncology Therapeutic Area
  • 10.3. Development in Genomics & Proteomics

11. Global Prostate Cancer Market - Challenges

  • 11.1. Costly Prostate Cancer Drugs
  • 11.2. Adverse Events of Treatment
  • 11.3. Low Success Rate for Oncology Drugs

LIST OF FIGURES:

  • Figure 3-1: Global - Prostate Cancer Drugs Market (Million US$), 2010 - 2014
  • Figure 3-2: Global - Forecast for Prostate Cancer Drugs Market (Million US$), 2015 - 2020
  • Figure 4-1: Global - Prostate Cancer Incidence (Number), 2007 - 2014
  • Figure 4-2: Global - Forecast for Prostate Cancer Incidence (Number), 2015 - 2020
  • Figure 6-1: Global - Zytiga Drugs Sales (Million US$), 2011 - 2014
  • Figure 6-2: Global - Forecast for Zytiga Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-3: Global - Gonax/ Firmagon Drugs Sales (Million US$), 2012 - 2014
  • Figure 6-4: Global - Forecast for Gonax Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-5: Global - Lupron Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-6: Global - Forecast for Lupron Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-7: Global - Zoladex Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-8: Global - Forecast for Zoladex Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-9: Global - Decapeptyl Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-10: Global - Forecast for Decapeptyl Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-11: Global - Eligard Drug Sales (Million US$), 2009 - 2014
  • Figure 6-12: Global - Forecast for Eligard Drug Sales (Million US$), 2015 - 2020
  • Figure 6-13: Global - Vantas Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-14: Global - Forecast for Vantas Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-15: Global - Leuplin Drugs Sales (Million US$), 2009 - 2014
  • Figure 6-16: Global - Forecast for Leuplin Drugs Sales (Million US$), 2015 - 2020
  • Figure 6-17: Global - Casodex Drug Sales (Million US$), 2009 - 2014
  • Figure 6-18: Global - Forecast for Casodex Drug Sales (Million US$), 2015 - 2020
  • Figure 6-19: Global - Xtandi or MDV3100 Drug Sales (Million US$), 2012 - 2014
  • Figure 6-20: Global - Forecast for Xtandi or MDV3100 Drug Sales (Million US$), 2015 - 2020
  • Figure 6-21: Global - Xtandi US or MDV3100 Drug Sales (Million US$), 2012 - 2014
  • Figure 6-22: Global - Forecast for Xtandi US or MDV3100 Drug Sales (Million US$), 2015 - 2020
  • Figure 7-1: Global - Taxotere Drug Sales (Million US$), 2011 - 2014
  • Figure 7-2: Global - Forecast for Taxotere Drug Sales (Million US$), 2015 - 2020
  • Figure 7-3: Global - Jevtana Drug Sales (Million US$), 2010 - 2014
  • Figure 7-4: Global - Forecast for Jevtana Drug Sales (Million US$), 2015 - 2020
  • Figure 8-1: Global - Provenge Drugs Sales (Million US$), 2011 - 2014
  • Figure 8-2: Global - Forecast for Provenge Drugs Sales (Million US$), 2015 - 2020
  • Figure 9-1: Global - Xofigo or Alpharadin Drug Sales (Million US$), 2013 - 2014
  • Figure 9-2: Global - Forecast for Xofigo or Alpharadin Drug Sales (Million US$), 2015 - 2020
  • Figure 11-1: Therapeutic Categories - Overall Success Rate from Phase 1 through Likelihood of Approval (Percent), 2004 - 2010

LIST OF TABLES

  • Table 5-1: Global - Prostate Cancer Drugs Market Share (Percent), 2011 - 2014
  • Table 5-2: Global - Forecast for Prostate Cancer Drugs Market Share (Percent), 2015 - 2020
Back to Top